Breast Cancer Screening and Diagnosis, Version 1.2023 Featured Updates to the NCCN Guidelines

Therese B. Bevers; Bethany L. Niell; Jennifer L. Baker; Debbie L. Bennett; Ermelinda Bonaccio; Melissa S. Camp; Sona Chikarmane; Emily F. Conant; Mohammad Eghtedari; Meghan R. Flanagan; Jeffrey Hawley; Mark Helvie; Linda Hodgkiss; Tamarya L. Hoyt; Jennifer Ivanovich; Maxine S. Jochelson; Swati Kulkarni; Rachael B. Lancaster; Caitlin Mauer; Jessica Maxwell; Bhavika K. Patel; Mark Pearlman; Liane Philpotts; Donna Plecha; Jennifer K. Plichta; Shadi Shakeri; Mary Lou Smith; Clarie L. Streibert; Roberta M. Strigel; Lusine Tumyan; Nicole S. Winkler; Dulcy E. Wolverton; Mary Anne Bergman; Rashmi Kumar; Katie Stehman

doi:10.6004/jnccn.2023.0046

Breast Cancer Screening and Diagnosis, Version 1.2023 Featured Updates to the NCCN Guidelines

Therese B. Bevers, Bethany L. Niell, Jennifer L. Baker, Debbie L. Bennett, Ermelinda Bonaccio, Melissa S. Camp, Sona Chikarmane, Emily F. Conant, Mohammad Eghtedari, Meghan R. Flanagan, Jeffrey Hawley, Mark Helvie, Linda Hodgkiss, Tamarya L. Hoyt, Jennifer Ivanovich, Maxine S. Jochelson, Swati Kulkarni, Rachael B. Lancaster, Caitlin Mauer, Jessica MaxwellBhavika K. Patel, Mark Pearlman, Liane Philpotts, Donna Plecha, Jennifer K. Plichta, Shadi Shakeri, Mary Lou Smith, Clarie L. Streibert, Roberta M. Strigel, Lusine Tumyan, Nicole S. Winkler, Dulcy E. Wolverton, Mary Anne Bergman, Rashmi Kumar, Katie Stehman

Research output: Contribution to journal › Article › peer-review

69 Scopus citations

Abstract

The NCCN Guidelines for Breast Cancer Screening and Diagnosis provide health care providers with a practical, consistent framework for screening and evaluating a spectrum of clinical presentations and breast lesions. The NCCN Breast Cancer Screening and Diagnosis Panel is composed of a multidisciplinary team of experts in the field, including representation from medical oncology, gynecologic oncology, surgical oncology, internal medicine, family practice, preventive medicine, pathology, diagnostic and interventional radiology, as well as patient advocacy. The NCCN Breast Cancer Screening and Diagnosis Panel meets at least annually to review emerging data and comments from reviewers within their institutions to guide updates to existing recommendations. These NCCN Guidelines Insights summarize the panel’s decision-making and discussion surrounding the most recent updates to the guideline’s screening recommendations.

Original language	English
Pages (from-to)	900-909
Number of pages	10
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	21
Issue number	9
DOIs	https://doi.org/10.6004/jnccn.2023.0046
State	Published - Sep 2023

Access to Document

10.6004/jnccn.2023.0046

Cite this

Bevers, T. B., Niell, B. L., Baker, J. L., Bennett, D. L., Bonaccio, E., Camp, M. S., Chikarmane, S., Conant, E. F., Eghtedari, M., Flanagan, M. R., Hawley, J., Helvie, M., Hodgkiss, L., Hoyt, T. L., Ivanovich, J., Jochelson, M. S., Kulkarni, S., Lancaster, R. B., Mauer, C., ... Stehman, K. (2023). Breast Cancer Screening and Diagnosis, Version 1.2023 Featured Updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 21(9), 900-909. https://doi.org/10.6004/jnccn.2023.0046

@article{aaf7ae9a8b1245638ef27e19971a98e8,

title = "Breast Cancer Screening and Diagnosis, Version 1.2023 Featured Updates to the NCCN Guidelines",

abstract = "The NCCN Guidelines for Breast Cancer Screening and Diagnosis provide health care providers with a practical, consistent framework for screening and evaluating a spectrum of clinical presentations and breast lesions. The NCCN Breast Cancer Screening and Diagnosis Panel is composed of a multidisciplinary team of experts in the field, including representation from medical oncology, gynecologic oncology, surgical oncology, internal medicine, family practice, preventive medicine, pathology, diagnostic and interventional radiology, as well as patient advocacy. The NCCN Breast Cancer Screening and Diagnosis Panel meets at least annually to review emerging data and comments from reviewers within their institutions to guide updates to existing recommendations. These NCCN Guidelines Insights summarize the panel{\textquoteright}s decision-making and discussion surrounding the most recent updates to the guideline{\textquoteright}s screening recommendations.",

author = "Bevers, {Therese B.} and Niell, {Bethany L.} and Baker, {Jennifer L.} and Bennett, {Debbie L.} and Ermelinda Bonaccio and Camp, {Melissa S.} and Sona Chikarmane and Conant, {Emily F.} and Mohammad Eghtedari and Flanagan, {Meghan R.} and Jeffrey Hawley and Mark Helvie and Linda Hodgkiss and Hoyt, {Tamarya L.} and Jennifer Ivanovich and Jochelson, {Maxine S.} and Swati Kulkarni and Lancaster, {Rachael B.} and Caitlin Mauer and Jessica Maxwell and Patel, {Bhavika K.} and Mark Pearlman and Liane Philpotts and Donna Plecha and Plichta, {Jennifer K.} and Shadi Shakeri and Smith, {Mary Lou} and Streibert, {Clarie L.} and Strigel, {Roberta M.} and Lusine Tumyan and Winkler, {Nicole S.} and Wolverton, {Dulcy E.} and Bergman, {Mary Anne} and Rashmi Kumar and Katie Stehman",

year = "2023",

month = sep,

doi = "10.6004/jnccn.2023.0046",

language = "English",

volume = "21",

pages = "900--909",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "9",

}

Bevers, TB, Niell, BL, Baker, JL, Bennett, DL, Bonaccio, E, Camp, MS, Chikarmane, S, Conant, EF, Eghtedari, M, Flanagan, MR, Hawley, J, Helvie, M, Hodgkiss, L, Hoyt, TL, Ivanovich, J, Jochelson, MS, Kulkarni, S, Lancaster, RB, Mauer, C, Maxwell, J, Patel, BK, Pearlman, M, Philpotts, L, Plecha, D, Plichta, JK, Shakeri, S, Smith, ML, Streibert, CL, Strigel, RM, Tumyan, L, Winkler, NS, Wolverton, DE, Bergman, MA, Kumar, R & Stehman, K 2023, 'Breast Cancer Screening and Diagnosis, Version 1.2023 Featured Updates to the NCCN Guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 21, no. 9, pp. 900-909. https://doi.org/10.6004/jnccn.2023.0046

TY - JOUR

T1 - Breast Cancer Screening and Diagnosis, Version 1.2023 Featured Updates to the NCCN Guidelines

AU - Bevers, Therese B.

AU - Niell, Bethany L.

AU - Baker, Jennifer L.

AU - Bennett, Debbie L.

AU - Bonaccio, Ermelinda

AU - Camp, Melissa S.

AU - Chikarmane, Sona

AU - Conant, Emily F.

AU - Eghtedari, Mohammad

AU - Flanagan, Meghan R.

AU - Hawley, Jeffrey

AU - Helvie, Mark

AU - Hodgkiss, Linda

AU - Hoyt, Tamarya L.

AU - Ivanovich, Jennifer

AU - Jochelson, Maxine S.

AU - Kulkarni, Swati

AU - Lancaster, Rachael B.

AU - Mauer, Caitlin

AU - Maxwell, Jessica

AU - Patel, Bhavika K.

AU - Pearlman, Mark

AU - Philpotts, Liane

AU - Plecha, Donna

AU - Plichta, Jennifer K.

AU - Shakeri, Shadi

AU - Smith, Mary Lou

AU - Streibert, Clarie L.

AU - Strigel, Roberta M.

AU - Tumyan, Lusine

AU - Winkler, Nicole S.

AU - Wolverton, Dulcy E.

AU - Bergman, Mary Anne

AU - Kumar, Rashmi

AU - Stehman, Katie

PY - 2023/9

Y1 - 2023/9

N2 - The NCCN Guidelines for Breast Cancer Screening and Diagnosis provide health care providers with a practical, consistent framework for screening and evaluating a spectrum of clinical presentations and breast lesions. The NCCN Breast Cancer Screening and Diagnosis Panel is composed of a multidisciplinary team of experts in the field, including representation from medical oncology, gynecologic oncology, surgical oncology, internal medicine, family practice, preventive medicine, pathology, diagnostic and interventional radiology, as well as patient advocacy. The NCCN Breast Cancer Screening and Diagnosis Panel meets at least annually to review emerging data and comments from reviewers within their institutions to guide updates to existing recommendations. These NCCN Guidelines Insights summarize the panel’s decision-making and discussion surrounding the most recent updates to the guideline’s screening recommendations.

AB - The NCCN Guidelines for Breast Cancer Screening and Diagnosis provide health care providers with a practical, consistent framework for screening and evaluating a spectrum of clinical presentations and breast lesions. The NCCN Breast Cancer Screening and Diagnosis Panel is composed of a multidisciplinary team of experts in the field, including representation from medical oncology, gynecologic oncology, surgical oncology, internal medicine, family practice, preventive medicine, pathology, diagnostic and interventional radiology, as well as patient advocacy. The NCCN Breast Cancer Screening and Diagnosis Panel meets at least annually to review emerging data and comments from reviewers within their institutions to guide updates to existing recommendations. These NCCN Guidelines Insights summarize the panel’s decision-making and discussion surrounding the most recent updates to the guideline’s screening recommendations.

UR - http://www.scopus.com/inward/record.url?scp=85169998380&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2023.0046

DO - 10.6004/jnccn.2023.0046

M3 - Article

C2 - 37673117

AN - SCOPUS:85169998380

SN - 1540-1405

VL - 21

SP - 900

EP - 909

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 9

ER -

Breast Cancer Screening and Diagnosis, Version 1.2023 Featured Updates to the NCCN Guidelines

Abstract

Access to Document

Other files and links

Fingerprint

Cite this